25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Apellis Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Apellis together

I guess you are interested in Apellis Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Apellis Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Apellis Pharmaceuticals Inc

I send you an email if I find something interesting about Apellis Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Apellis (30 sec.)










1.2. What can you expect buying and holding a share of Apellis? (30 sec.)

How much money do you get?

How much money do you get?
$0.01
When do you have the money?
1 year
How often do you get paid?
8.3%

What is your share worth?

Current worth
$1.91
Expected worth in 1 year
$1.95
How sure are you?
36.1%

+ What do you gain per year?

Total Gains per Share
$0.05
Return On Investment
0.1%

For what price can you sell your share?

Current Price per Share
$35.02
Expected price per share
$24.34 - $41.94
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Apellis (5 min.)




Live pricePrice per Share (EOD)
$35.02
Intrinsic Value Per Share
$49.20 - $60.85
Total Value Per Share
$51.10 - $62.75

2.2. Growth of Apellis (5 min.)




Is Apellis growing?

Current yearPrevious yearGrowGrow %
How rich?$237.1m$289.9m-$49.2m-20.5%

How much money is Apellis making?

Current yearPrevious yearGrowGrow %
Making money-$62.5m-$151.5m$88.9m142.3%
Net Profit Margin-36.8%-349.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Apellis (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#226 / 945

Most Revenue
#58 / 945

Most Profit
#859 / 945

Most Efficient
#376 / 945
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Apellis?

Welcome investor! Apellis's management wants to use your money to grow the business. In return you get a share of Apellis.

First you should know what it really means to hold a share of Apellis. And how you can make/lose money.

Speculation

The Price per Share of Apellis is $35.02. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Apellis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Apellis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.91. Based on the TTM, the Book Value Change Per Share is $0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Apellis.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.46-1.3%-0.50-1.4%-1.22-3.5%-1.02-2.9%-0.67-1.9%
Usd Book Value Change Per Share-0.22-0.6%0.010.0%-0.15-0.4%0.040.1%0.050.1%
Usd Dividend Per Share0.000.0%0.000.0%0.040.1%0.010.0%0.000.0%
Usd Total Gains Per Share-0.22-0.6%0.010.0%-0.11-0.3%0.050.1%0.060.2%
Usd Price Per Share28.84-46.46-61.70-48.04-31.29-
Price to Earnings Ratio-15.61--23.96--13.22--10.89--9.60-
Price-to-Total Gains Ratio-131.86--566.92--58.75--148.56--119.23-
Price to Book Ratio15.13-24.72-27.74-24.29-16.96-
Price-to-Total Gains Ratio-131.86--566.92--58.75--148.56--119.23-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share35.02
Number of shares28
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share0.010.04
Usd Total Gains Per Share0.010.05
Gains per Quarter (28 shares)0.361.32
Gains per Year (28 shares)1.445.28
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101-914-5
212-8290
313-73135
414-641810
525-542215
627-452620
728-363125
839-273530
9310-184035
10411094440

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%2.034.00.05.6%2.035.01.05.3%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%13.022.01.036.1%14.022.02.036.8%
Dividend per Share1.00.03.025.0%3.00.09.025.0%3.00.017.015.0%3.00.033.08.3%3.00.035.07.9%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%13.022.01.036.1%14.022.02.036.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Apellis Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.2190.010-2344%-0.151-31%0.039-658%0.052-521%
Book Value Per Share--1.9061.935-1%2.331-18%1.653+15%1.264+51%
Current Ratio--4.3604.077+7%5.143-15%6.793-36%9.000-52%
Debt To Asset Ratio--0.7370.719+2%0.674+9%0.771-4%0.555+33%
Debt To Equity Ratio--2.8032.600+8%2.256+24%3.380-17%2.085+34%
Dividend Per Share---0.003-100%0.036-100%0.008-100%0.004-100%
Enterprise Value--3319613120.0005522611780.000-40%7693445582.500-57%5967574319.550-44%5042391595.857-34%
Eps---0.462-0.503+9%-1.218+164%-1.024+122%-0.672+45%
Ev To Ebitda Ratio---18.920-28.049+48%-13.755-27%-13.521-29%-15.488-18%
Ev To Sales Ratio--4.2168.102-48%39.730-89%infnan%infnan%
Free Cash Flow Per Share--0.274-0.413+251%-1.285+569%-0.816+398%-0.528+293%
Free Cash Flow To Equity Per Share--0.295-0.113+138%-0.516+275%-0.013+104%0.099+197%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--60.845--------
Intrinsic Value_10Y_min--49.195--------
Intrinsic Value_1Y_max---2.171--------
Intrinsic Value_1Y_min---2.137--------
Intrinsic Value_3Y_max---0.221--------
Intrinsic Value_3Y_min---0.338--------
Intrinsic Value_5Y_max--9.325--------
Intrinsic Value_5Y_min--8.113--------
Market Cap4356242860.000+18%3587494120.0005779298780.000-38%7675359082.500-53%5975653130.500-40%3892395184.444-8%
Net Profit Margin---0.292-0.368+26%-3.497+1098%7.723-104%-127.391+43549%
Operating Margin---0.226-0.314+39%-3.463+1432%7.973-103%-122.691+54186%
Operating Ratio--1.2401.331-7%4.477-72%-3.643+394%130.799-99%
Pb Ratio18.371+18%15.12924.720-39%27.739-45%24.285-38%16.962-11%
Pe Ratio-18.958-21%-15.613-23.957+53%-13.219-15%-10.885-30%-9.600-39%
Price Per Share35.020+18%28.84046.460-38%61.703-53%48.039-40%31.291-8%
Price To Free Cash Flow Ratio31.941+18%26.304-36.985+241%-12.176+146%-15.355+158%-13.302+151%
Price To Total Gains Ratio-160.121-21%-131.864-566.916+330%-58.753-55%-148.555+13%-119.233-10%
Quick Ratio--3.5603.160+13%4.229-16%7.862-55%9.293-62%
Return On Assets---0.064-0.074+17%-0.176+177%-0.167+163%-0.262+312%
Return On Equity---0.242-0.272+12%-0.591+144%-0.726+200%-0.603+149%
Total Gains Per Share---0.2190.013-1798%-0.115-48%0.047-564%0.056-488%
Usd Book Value--237121000.000240661250.000-1%289917250.000-18%205678633.800+15%157195326.611+51%
Usd Book Value Change Per Share---0.2190.010-2344%-0.151-31%0.039-658%0.052-521%
Usd Book Value Per Share--1.9061.935-1%2.331-18%1.653+15%1.264+51%
Usd Dividend Per Share---0.003-100%0.036-100%0.008-100%0.004-100%
Usd Enterprise Value--3319613120.0005522611780.000-40%7693445582.500-57%5967574319.550-44%5042391595.857-34%
Usd Eps---0.462-0.503+9%-1.218+164%-1.024+122%-0.672+45%
Usd Free Cash Flow--34096000.000-51394750.000+251%-159783250.000+569%-101537623.450+398%-65712614.556+293%
Usd Free Cash Flow Per Share--0.274-0.413+251%-1.285+569%-0.816+398%-0.528+293%
Usd Free Cash Flow To Equity Per Share--0.295-0.113+138%-0.516+275%-0.013+104%0.099+197%
Usd Market Cap4356242860.000+18%3587494120.0005779298780.000-38%7675359082.500-53%5975653130.500-40%3892395184.444-8%
Usd Price Per Share35.020+18%28.84046.460-38%61.703-53%48.039-40%31.291-8%
Usd Profit---57445000.000-62525250.000+9%-151510750.000+164%-127338521.150+122%-82574800.583+44%
Usd Revenue--196830000.000178804250.000+10%65415000.000+201%67335142.500+192%37409053.722+426%
Usd Total Gains Per Share---0.2190.013-1798%-0.115-48%0.047-564%0.056-488%
 EOD+4 -4MRQTTM+20 -19YOY+17 -225Y+20 -1810Y+20 -18

3.3 Fundamental Score

Let's check the fundamental score of Apellis Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-18.958
Price to Book Ratio (EOD)Between0-118.371
Net Profit Margin (MRQ)Greater than0-0.292
Operating Margin (MRQ)Greater than0-0.226
Quick Ratio (MRQ)Greater than13.560
Current Ratio (MRQ)Greater than14.360
Debt to Asset Ratio (MRQ)Less than10.737
Debt to Equity Ratio (MRQ)Less than12.803
Return on Equity (MRQ)Greater than0.15-0.242
Return on Assets (MRQ)Greater than0.05-0.064
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Apellis Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.764
Ma 20Greater thanMa 5031.068
Ma 50Greater thanMa 10029.087
Ma 100Greater thanMa 20033.037
OpenGreater thanClose33.800
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Fundamental data was last updated by Penke on 2024-12-05 12:35:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Apellis earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Apellis to the Biotechnology industry mean.
  • A Net Profit Margin of -29.2% means that $-0.29 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Apellis Pharmaceuticals Inc:

  • The MRQ is -29.2%. The company is making a huge loss. -2
  • The TTM is -36.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-29.2%TTM-36.8%+7.6%
TTM-36.8%YOY-349.7%+312.9%
TTM-36.8%5Y772.3%-809.1%
5Y772.3%10Y-12,739.1%+13,511.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.2%-109.4%+80.2%
TTM-36.8%-221.4%+184.6%
YOY-349.7%-208.7%-141.0%
5Y772.3%-346.2%+1,118.5%
10Y-12,739.1%-470.4%-12,268.7%
4.3.1.2. Return on Assets

Shows how efficient Apellis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Apellis to the Biotechnology industry mean.
  • -6.4% Return on Assets means that Apellis generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Apellis Pharmaceuticals Inc:

  • The MRQ is -6.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.4%TTM-7.4%+1.1%
TTM-7.4%YOY-17.6%+10.2%
TTM-7.4%5Y-16.7%+9.3%
5Y-16.7%10Y-26.2%+9.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.4%-11.6%+5.2%
TTM-7.4%-12.0%+4.6%
YOY-17.6%-11.2%-6.4%
5Y-16.7%-12.6%-4.1%
10Y-26.2%-14.2%-12.0%
4.3.1.3. Return on Equity

Shows how efficient Apellis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Apellis to the Biotechnology industry mean.
  • -24.2% Return on Equity means Apellis generated $-0.24 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Apellis Pharmaceuticals Inc:

  • The MRQ is -24.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -27.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-24.2%TTM-27.2%+3.0%
TTM-27.2%YOY-59.1%+31.9%
TTM-27.2%5Y-72.6%+45.3%
5Y-72.6%10Y-60.3%-12.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24.2%-14.5%-9.7%
TTM-27.2%-16.0%-11.2%
YOY-59.1%-14.6%-44.5%
5Y-72.6%-18.6%-54.0%
10Y-60.3%-19.3%-41.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Apellis Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Apellis is operating .

  • Measures how much profit Apellis makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Apellis to the Biotechnology industry mean.
  • An Operating Margin of -22.6% means the company generated $-0.23  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Apellis Pharmaceuticals Inc:

  • The MRQ is -22.6%. The company is operating very inefficient. -2
  • The TTM is -31.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-22.6%TTM-31.4%+8.8%
TTM-31.4%YOY-346.3%+314.9%
TTM-31.4%5Y797.3%-828.7%
5Y797.3%10Y-12,269.1%+13,066.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.6%-203.3%+180.7%
TTM-31.4%-316.3%+284.9%
YOY-346.3%-216.5%-129.8%
5Y797.3%-378.6%+1,175.9%
10Y-12,269.1%-480.3%-11,788.8%
4.3.2.2. Operating Ratio

Measures how efficient Apellis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.24 means that the operating costs are $1.24 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Apellis Pharmaceuticals Inc:

  • The MRQ is 1.240. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.331. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.240TTM1.331-0.091
TTM1.331YOY4.477-3.145
TTM1.3315Y-3.643+4.974
5Y-3.64310Y130.799-134.442
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2402.284-1.044
TTM1.3313.198-1.867
YOY4.4773.263+1.214
5Y-3.6434.651-8.294
10Y130.7996.419+124.380
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Apellis Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Apellis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.36 means the company has $4.36 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Apellis Pharmaceuticals Inc:

  • The MRQ is 4.360. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.077. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.360TTM4.077+0.283
TTM4.077YOY5.143-1.066
TTM4.0775Y6.793-2.716
5Y6.79310Y9.000-2.207
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.3603.601+0.759
TTM4.0773.872+0.205
YOY5.1434.655+0.488
5Y6.7935.973+0.820
10Y9.0006.258+2.742
4.4.3.2. Quick Ratio

Measures if Apellis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Apellis to the Biotechnology industry mean.
  • A Quick Ratio of 3.56 means the company can pay off $3.56 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Apellis Pharmaceuticals Inc:

  • The MRQ is 3.560. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.160. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.560TTM3.160+0.399
TTM3.160YOY4.229-1.069
TTM3.1605Y7.862-4.702
5Y7.86210Y9.293-1.431
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5603.093+0.467
TTM3.1603.416-0.256
YOY4.2294.393-0.164
5Y7.8625.954+1.908
10Y9.2936.436+2.857
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Apellis Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Apellis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Apellis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.74 means that Apellis assets are financed with 73.7% credit (debt) and the remaining percentage (100% - 73.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Apellis Pharmaceuticals Inc:

  • The MRQ is 0.737. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.719. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.737TTM0.719+0.018
TTM0.719YOY0.674+0.046
TTM0.7195Y0.771-0.052
5Y0.77110Y0.555+0.216
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7370.345+0.392
TTM0.7190.346+0.373
YOY0.6740.311+0.363
5Y0.7710.365+0.406
10Y0.5550.382+0.173
4.5.4.2. Debt to Equity Ratio

Measures if Apellis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Apellis to the Biotechnology industry mean.
  • A Debt to Equity ratio of 280.3% means that company has $2.80 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Apellis Pharmaceuticals Inc:

  • The MRQ is 2.803. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.600. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.803TTM2.600+0.204
TTM2.600YOY2.256+0.344
TTM2.6005Y3.380-0.780
5Y3.38010Y2.085+1.295
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8030.393+2.410
TTM2.6000.431+2.169
YOY2.2560.384+1.872
5Y3.3800.452+2.928
10Y2.0850.497+1.588
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Apellis generates.

  • Above 15 is considered overpriced but always compare Apellis to the Biotechnology industry mean.
  • A PE ratio of -15.61 means the investor is paying $-15.61 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Apellis Pharmaceuticals Inc:

  • The EOD is -18.958. Based on the earnings, the company is expensive. -2
  • The MRQ is -15.613. Based on the earnings, the company is expensive. -2
  • The TTM is -23.957. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-18.958MRQ-15.613-3.346
MRQ-15.613TTM-23.957+8.344
TTM-23.957YOY-13.219-10.738
TTM-23.9575Y-10.885-13.072
5Y-10.88510Y-9.600-1.285
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-18.958-2.259-16.699
MRQ-15.613-2.480-13.133
TTM-23.957-3.148-20.809
YOY-13.219-3.244-9.975
5Y-10.885-5.991-4.894
10Y-9.600-6.692-2.908
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Apellis Pharmaceuticals Inc:

  • The EOD is 31.941. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 26.304. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is -36.985. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD31.941MRQ26.304+5.637
MRQ26.304TTM-36.985+63.289
TTM-36.985YOY-12.176-24.809
TTM-36.9855Y-15.355-21.630
5Y-15.35510Y-13.302-2.053
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD31.941-2.995+34.936
MRQ26.304-3.289+29.593
TTM-36.985-3.668-33.317
YOY-12.176-4.472-7.704
5Y-15.355-8.001-7.354
10Y-13.302-9.190-4.112
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Apellis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 15.13 means the investor is paying $15.13 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Apellis Pharmaceuticals Inc:

  • The EOD is 18.371. Based on the equity, the company is expensive. -2
  • The MRQ is 15.129. Based on the equity, the company is expensive. -2
  • The TTM is 24.720. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD18.371MRQ15.129+3.242
MRQ15.129TTM24.720-9.591
TTM24.720YOY27.739-3.019
TTM24.7205Y24.285+0.435
5Y24.28510Y16.962+7.324
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD18.3712.001+16.370
MRQ15.1292.054+13.075
TTM24.7202.385+22.335
YOY27.7392.431+25.308
5Y24.2853.690+20.595
10Y16.9624.307+12.655
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Apellis Pharmaceuticals Inc.

4.8.1. Institutions holding Apellis Pharmaceuticals Inc

Institutions are holding 99.138% of the shares of Apellis Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Wellington Management Company LLP12.51430.078615566969-821728-5.014
2024-09-30EcoR1 Capital, LLC9.559111.7379118908432834182.4417
2024-09-30venBio Select Advisor LLC8.93234.67251111111100
2024-09-30Vanguard Group Inc7.89080.0051981557560230.0614
2024-06-30BlackRock Inc4.65880.00557952723006815.4723
2024-09-30Deep Track Capital, LP3.53774.02564400654190065476.0262
2024-09-30State Street Corp3.24850.00474040861-105833-2.5522
2024-09-30JPMorgan Chase & Co3.12290.0085388473070726022.2586
2024-09-30Morgan Stanley - Brokerage Accounts2.72510.00713389785-848009-20.0106
2024-09-30BRAIDWELL LP2.51232.554731251832513383410.8178
2024-09-30Octagon Capital Advisors LP2.417313.489130069801261004.3771
2024-09-30T. Rowe Price Investment Management,Inc.2.39990.05192985272-1063140-26.2607
2024-09-30FMR Inc2.33150.00512900254-399536-12.1079
2024-09-30Assenagon Asset Management SA1.72390.113821444151409707191.8731
2024-06-30Deutsche Bank AG1.48080.0319184204223026914.2867
2024-09-30Jennison Associates LLC1.4640.03261821115-1770301-49.2926
2024-09-30Geode Capital Management, LLC1.45550.00421810526226091.2645
2024-09-30Boxer Capital LLC1.38752.4428172600000
2024-06-30Fiera Capital Corporation1.12640.1682140119045275347.7368
2024-09-30Orbimed Advisors, LLC1.02130.66571270400-32400-2.487
Total 75.509940.10593929177+2911910+3.1%

4.9.2. Funds holding Apellis Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Vanguard Health Care Inv8.11030.5974100886005852256.1581
2024-10-31Vanguard Total Stock Mkt Idx Inv2.6390.00523282746-18537-0.5615
2024-10-31Vanguard Small Cap Index2.08590.0465259465351000.1969
2024-11-27SPDR® S&P Biotech ETF1.79841.0292237037-67950-2.948
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.25950.03941566759-5858-0.3725
2024-10-31Vanguard Small Cap Growth Index Inv1.14620.10711425792-2920-0.2044
2024-10-31DWS Vermögensbildungsfonds I LD1.06120.2244132004120.0002
2024-09-30JPMorgan Mid Cap Growth I1.04720.3382130261000
2024-09-30JPM US Mid Cap Growth-Composite1.04720.3381130261029466029.2336
2024-09-30T. Rowe Price Mid-Cap Growth0.96170.111196243-144257-10.7614
2024-09-30T. Rowe Price US Mid-Cap Growth Equity0.96170.111196243-145157-10.8213
2024-10-31Polar Capital Biotech S Inc0.80391.4029100000000
2024-09-30Vanguard Explorer Inv0.79310.1265986546269252.8058
2024-08-31Worldwide Healthcare Ord0.73241.260591100000
2024-09-30Fidelity Select Biotechnology0.5880.4261731422-224657-23.4977
2024-10-31Wellington Global Hlthcr Eq USD G Ac0.56360.844270108500
2024-11-27iShares Biotechnology ETF0.55970.34116962207080.1018
2024-09-30JPMorgan Small Cap Growth A0.53590.526966665800
2024-10-31State St Russell Sm/Mid Cp® Indx NL Cl C0.52130.0393648446-23000-3.4254
2024-09-30Fiera SMID Growth0.49861.1306620219-31463-4.828
Total 27.71489.043434474930+248821+0.7%

5.3. Insider Transactions

Insiders are holding 13.976% of the shares of Apellis Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-09-16A. Sinclair DunlopSELL3700036.23
2024-06-21A. Sinclair DunlopSELL3700039.24
2024-05-08Pascal DeschateletsSELL7890742.35
2024-04-08Pascal DeschateletsSELL6910754.17
2024-04-01Timothy Eugene SullivanSELL400058.66
2024-03-19A. Sinclair DunlopSELL1868157.18
2024-03-18Mark Jeffrey DelongSELL991356.9
2024-03-15James George ChopasSELL18456.46
2024-03-13Nur NicholsonSELL1122057.56
2024-03-01Cedric FrancoisSELL25000064.11
2024-03-01Timothy Eugene SullivanSELL600063.22
2024-02-12Adam J TownsendSELL114867.77
2024-02-12Cedric FrancoisSELL396267.77
2024-02-12David O WatsonSELL78167.77
2024-02-12Timothy Eugene SullivanSELL143167.77
2024-01-29Cedric FrancoisSELL284364.14
2024-01-29Nur NicholsonSELL83564.14
2024-01-29David O WatsonSELL90664.14
2024-01-22Adam J TownsendSELL341365
2024-01-22Cedric FrancoisSELL1343165
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets901,866
Total Liabilities664,745
Total Stockholder Equity237,121
 As reported
Total Liabilities 664,745
Total Stockholder Equity+ 237,121
Total Assets = 901,866

Assets

Total Assets901,866
Total Current Assets833,897
Long-term Assets67,969
Total Current Assets
Cash And Cash Equivalents 396,864
Net Receivables 283,969
Inventory 121,058
Other Current Assets 32,006
Total Current Assets  (as reported)833,897
Total Current Assets  (calculated)833,897
+/-0
Long-term Assets
Property Plant Equipment 20,439
Long-term Assets Other 47,530
Long-term Assets  (as reported)67,969
Long-term Assets  (calculated)67,969
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities191,260
Long-term Liabilities473,485
Total Stockholder Equity237,121
Total Current Liabilities
Short-term Debt 13,584
Accounts payable 42,730
Other Current Liabilities 133,043
Total Current Liabilities  (as reported)191,260
Total Current Liabilities  (calculated)189,357
+/- 1,903
Long-term Liabilities
Long-term Liabilities  (as reported)473,485
Long-term Liabilities  (calculated)0
+/- 473,485
Total Stockholder Equity
Common Stock12
Retained Earnings -2,999,013
Accumulated Other Comprehensive Income -3,140
Other Stockholders Equity 3,239,262
Total Stockholder Equity (as reported)237,121
Total Stockholder Equity (calculated)237,121
+/-0
Other
Cash and Short Term Investments 396,864
Common Stock Shares Outstanding 123,904
Current Deferred Revenue1,903
Liabilities and Stockholders Equity 901,866
Net Debt 73,584
Net Working Capital 642,637
Short Long Term Debt Total 470,448



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302015-12-312015-09-302015-06-302014-12-312014-09-302013-12-31
> Total Assets 
5,199
0
14,306
16,818
13,742
38,177
0
27,433
9,445
56,692
19,141
182,131
163,203
266,818
239,146
203,534
318,353
316,704
466,357
389,245
688,939
870,106
768,334
960,569
810,129
699,912
525,689
881,765
1,145,854
1,002,498
872,892
760,217
978,869
915,578
818,216
788,730
831,930
904,482
901,866
901,866904,482831,930788,730818,216915,578978,869760,217872,8921,002,4981,145,854881,765525,689699,912810,129960,569768,334870,106688,939389,245466,357316,704318,353203,534239,146266,818163,203182,13119,14156,6929,44527,433038,17713,74216,81814,30605,199
   > Total Current Assets 
0
0
14,247
16,711
13,572
38,044
0
27,369
9,318
56,566
19,033
182,015
163,087
266,702
238,933
202,439
310,528
308,413
451,195
373,095
672,407
853,825
742,349
917,192
773,625
655,126
475,427
824,047
1,103,982
959,969
831,937
719,523
954,255
892,686
796,767
766,331
811,428
859,974
833,897
833,897859,974811,428766,331796,767892,686954,255719,523831,937959,9691,103,982824,047475,427655,126773,625917,192742,349853,825672,407373,095451,195308,413310,528202,439238,933266,702163,087182,01519,03356,5669,31827,369038,04413,57216,71114,24700
       Cash And Cash Equivalents 
4,758
0
13,623
14,865
10,032
36,004
0
24,863
4,939
52,186
13,136
175,644
152,931
253,840
220,641
176,268
288,247
289,129
433,995
351,985
417,881
317,348
415,560
565,779
265,435
270,764
283,745
640,192
633,456
604,489
584,189
551,801
765,083
616,259
452,414
352,299
327,026
361,426
396,864
396,864361,426327,026352,299452,414616,259765,083551,801584,189604,489633,456640,192283,745270,764265,435565,779415,560317,348417,881351,985433,995289,129288,247176,268220,641253,840152,931175,64413,13652,1864,93924,863036,00410,03214,86513,62304,758
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
228,813
515,476
312,598
311,869
458,237
328,246
146,566
60,358
331,842
248,307
124,364
6,505
9,041
9,423
13,116
4,354
7,620
7,954
0
07,9547,6204,35413,1169,4239,0416,505124,364248,307331,84260,358146,566328,246458,237311,869312,598515,476228,81300000000000000000000
       Net Receivables 
0
0
466
1,486
1,550
1,757
0
1,348
1,764
1,764
2,244
1,297
1,829
1,997
1,364
1,474
1,756
1,951
0
0
0
0
0
0
20,000
719
3,522
10,103
6,330
7,518
8,091
7,727
31,505
110,913
186,989
206,442
267,837
308,851
283,969
283,969308,851267,837206,442186,989110,91331,5057,7278,0917,5186,33010,1033,52271920,0000000001,9511,7561,4741,3641,9971,8291,2972,2441,7641,7641,34801,7571,5501,48646600
       Inventory 
0
0
137
311
1,931
0
0
0
0
0
0
0
6,293
8,860
15,482
0
0
0
0
0
0
0
0
0
0
3,731
1,677
16,286
32,850
48,451
59,753
85,714
85,484
103,216
98,545
146,362
161,283
152,772
121,058
121,058152,772161,283146,36298,545103,21685,48485,71459,75348,45132,85016,2861,6773,731000000000015,4828,8606,29300000001,93131113700
   > Long-term Assets 
0
0
59
107
171
133
0
65
0
126
108
116
116
116
213
1,094
7,825
8,291
15,162
16,150
16,532
16,281
25,985
43,377
36,504
44,786
50,262
57,718
41,872
42,529
40,955
40,694
24,614
22,892
21,449
22,399
20,502
44,508
67,969
67,96944,50820,50222,39921,44922,89224,61440,69440,95542,52941,87257,71850,26244,78636,50443,37725,98516,28116,53216,15015,1628,2917,8251,09421311611611610812606501331711075900
       Property Plant Equipment 
9
0
22
20
21
0
0
0
0
0
0
0
0
0
0
0
7,663
8,083
14,926
15,765
15,687
15,375
25,076
24,522
29,595
28,689
27,439
26,078
25,865
26,647
25,203
24,895
23,821
22,065
20,274
21,090
19,189
20,157
20,439
20,43920,15719,18921,09020,27422,06523,82124,89525,20326,64725,86526,07827,43928,68929,59524,52225,07615,37515,68715,76514,9268,0837,6630000000000021202209
       Other Assets 
0
0
37
0
150
133
0
64
126
127
108
116
116
116
213
1,094
162
208
237
385
845
906
909
18,855
6,909
16,097
22,823
31,640
16,007
15,882
15,752
15,799
0
0
0
0
0
0
0
000000015,79915,75215,88216,00731,64022,82316,0976,90918,8559099068453852372081621,09421311611611610812712664013315003700
> Total Liabilities 
677
0
1,082
1,271
2,656
3,200
0
3,639
6,118
32,688
6,938
33,189
34,161
37,266
43,191
42,561
93,598
157,618
326,795
355,015
429,942
638,042
662,494
756,012
758,471
841,405
583,014
683,103
683,619
668,080
565,476
590,345
566,746
570,175
585,945
594,209
565,254
640,155
664,745
664,745640,155565,254594,209585,945570,175566,746590,345565,476668,080683,619683,103583,014841,405758,471756,012662,494638,042429,942355,015326,795157,61893,59842,56143,19137,26634,16133,1896,93832,6886,1183,63903,2002,6561,2711,0820677
   > Total Current Liabilities 
677
0
1,082
1,271
2,656
3,200
0
3,639
6,118
6,118
6,938
6,554
7,295
10,254
16,034
17,025
20,386
35,591
44,572
65,753
50,740
57,990
75,273
128,327
83,670
157,787
94,237
131,847
124,769
126,793
115,446
167,610
138,644
174,837
185,630
247,593
215,291
169,168
191,260
191,260169,168215,291247,593185,630174,837138,644167,610115,446126,793124,769131,84794,237157,78783,670128,32775,27357,99050,74065,75344,57235,59120,38617,02516,03410,2547,2956,5546,9386,1186,1183,63903,2002,6561,2711,0820677
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
26,390
26,616
26,761
0
1,667
1,128
1,550
2,304
2,609
2,732
2,664
3,438
3,685
3,902
4,035
4,072
4,115
4,560
5,312
5,423
5,625
5,828
5,852
5,739
6,441
6,257
12,428
13,584
13,58412,4286,2576,4415,7395,8525,8285,6255,4235,3124,5604,1154,0724,0353,9023,6853,4382,6642,7322,6092,3041,5501,1281,667026,76126,61626,39000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
26,390
26,616
26,761
0
1,667
1,128
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000001,1281,667026,76126,61626,39000000000000
       Accounts payable 
354
0
752
830
1,268
2,477
0
2,547
2,604
2,604
4,001
3,663
4,585
5,133
5,469
10,255
11,916
13,812
11,837
8,361
3,078
9,927
11,069
8,477
4,158
5,339
4,984
16,909
12,273
16,220
14,099
37,342
31,494
27,500
18,192
37,516
26,788
38,270
42,730
42,73038,27026,78837,51618,19227,50031,49437,34214,09916,22012,27316,9094,9845,3394,1588,47711,0699,9273,0788,36111,83713,81211,91610,2555,4695,1334,5853,6634,0012,6042,6042,54702,4771,2688307520354
       Other Current Liabilities 
323
0
330
441
1,389
723
0
1,092
0
3,514
2,937
2,891
2,710
5,121
10,566
5,103
7,343
20,230
30,432
54,783
44,930
45,399
60,766
4,230
6,212
14,110
15,334
7,584
107,936
105,261
95,924
124,643
101,322
43,769
44,610
203,636
178,686
116,567
133,043
133,043116,567178,686203,63644,61043,769101,322124,64395,924105,261107,9367,58415,33414,1106,2124,23060,76645,39944,93054,78330,43220,2307,3435,10310,5665,1212,7102,8912,9373,51401,09207231,3894413300323
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
26,570
0
26,635
26,866
27,011
27,156
25,536
73,212
122,027
282,223
289,262
379,202
580,052
587,221
627,685
674,801
683,618
488,777
551,256
558,850
541,287
450,030
422,735
428,102
395,338
400,315
346,616
349,963
470,987
473,485
473,485470,987349,963346,616400,315395,338428,102422,735450,030541,287558,850551,256488,777683,618674,801627,685587,221580,052379,202289,262282,223122,02773,21225,53627,15627,01126,86626,635026,570000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
25,378
6,674
6,693
140,615
142,567
144,561
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000144,561142,567140,6156,6936,67425,378000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
244
250
250
250
159
60,971
110,090
130,353
134,839
223,245
220,475
217,778
253,638
268,740
278,022
281,017
345,151
352,992
335,298
342,080
315,647
0
0
0
0
0
0
0
0000000315,647342,080335,298352,992345,151281,017278,022268,740253,638217,778220,475223,245134,839130,353110,09060,97115925025025024400000000000
> Total Stockholder Equity
4,522
0
13,225
15,547
11,086
34,977
0
23,794
-68,261
24,003
12,203
148,943
129,042
229,552
195,955
160,973
224,755
159,086
139,562
34,230
258,997
232,064
105,840
204,557
51,658
-141,493
-57,325
198,662
462,235
334,418
307,416
169,872
412,123
345,403
232,271
194,521
266,676
264,327
237,121
237,121264,327266,676194,521232,271345,403412,123169,872307,416334,418462,235198,662-57,325-141,49351,658204,557105,840232,064258,99734,230139,562159,086224,755160,973195,955229,552129,042148,94312,20324,003-68,26123,794034,97711,08615,54713,22504,522
   Common Stock
1
0
1
1
2
1
0
1
2
4
1
5
5
6
6
6
6
6
6
6
7
8
8
8
8
8
9
10
11
11
11
11
12
12
12
12
12
12
12
121212121212121111111110988888766666665514210121101
   Retained Earnings Total Equity000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-22
-25
-28
0
0
0
0
0
0
0
0
0
340
-123
-121
-122
-205
-154
1,010
329
-1,759
-117
-1,620
-1,829
-2,010
-2,090
-2,059
-3,194
-3,027
-875
-775
-796
-1,065
-3,542
-3,525
-3,362
-3,140
-3,140-3,362-3,525-3,542-1,065-796-775-875-3,027-3,194-2,059-2,090-2,010-1,829-1,620-117-1,7593291,010-154-205-122-121-123340000000000-28-25-2200
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
437,856
552,209
557,632
608,016
615,850
1,008,275
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000001,008,275615,850608,016557,632552,209437,856000000000000000
   Treasury Stock000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
1,998
2,158
28,887
28,917
0
29,996
0
143,434
31,407
298,201
300,037
433,881
435,916
437,856
552,209
557,632
608,016
615,850
1,008,275
1,100,639
1,112,203
1,131,013
1,147,263
1,173,512
1,453,431
1,857,430
2,259,906
2,289,201
2,453,301
2,479,596
2,899,524
2,954,862
2,982,236
3,035,539
3,174,100
3,209,245
3,239,262
3,239,2623,209,2453,174,1003,035,5392,982,2362,954,8622,899,5242,479,5962,453,3012,289,2012,259,9061,857,4301,453,4311,173,5121,147,2631,131,0131,112,2031,100,6391,008,275615,850608,016557,632552,209437,856435,916433,881300,037298,20131,407143,434029,996028,91728,8872,1581,99800



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.